市場調査レポート

単純疱疹ウィルス治療の世界市場

Herpes Simplex Virus Treatment

発行 Global Industry Analysts, Inc. 商品コード 240212
出版日 ページ情報 英文 300 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
単純疱疹ウィルス治療の世界市場 Herpes Simplex Virus Treatment
出版日: 2012年04月01日 ページ情報: 英文 300 Pages
概要

当レポートでは、単純疱疹ウィルス治療の世界市場を分析し、米国/欧州/その他の地域についての包括的な地域別分析を提供し、2009-2017年間の年間業績を推定/予測するとともに6年間の歴史的分析、及び主要/ニッチプレーヤ38社の企業プロファイルを盛り込み、概略下記の構成でお届けいたします。

第1章 イントロダクション、方法論、製品定義

第2章 エグゼクティブサマリ

第3章 業界概要

  • 単純疱疹ウィルス感染症:序章
  • 罹患率
  • HSVの治療
  • 主要HSV治療薬の特許失効
  • ジェネリックとの競合による主要HSV治療薬 (Valtrex) の売上低下
  • HSV2パイプライン分析

第4章 単純疱疹ウィルス感染症の治療

  • 抗ウィルス治療
  • 主要薬剤
  • ワクチン接種
  • 自然療法
  • その他の治療法

第5章 HSVワクチン:分析

第6章 単純疱疹ウィルス感染症:疾病、原因、症状、診断

  • イントロダクション
  • ヘルペス・ウィルスの構造
  • ヘルペス・ウィルスの生物学的特性
  • ヒト・ヘルペス・ウィルスの多様なタイプ
  • ヘルペス・ウィルス群の潜伏期間
  • 抗体反応
  • HSV-1/HSV-2感染
  • 原因
  • 多様なタイプのヘルペス感染
  • 口腔ヘルペス
  • 口唇HSV感染
  • 性器感染
  • HSV中枢神経系感染
  • 青年レスラーの剣状ヘルペス
  • 急性ヘルペス感染
  • 新生児のHSV感染
  • 播種性HSV疾患
  • その他のHSV感染
  • 異なる年齢集団におけるHSV感染
  • 妊婦のHSV感染
  • 免疫不全患者におけるHSV
  • 罹患率と死亡率
  • 単純疱疹ウィルス感染症の重症度
  • 予防策
  • HSV感染の診断
  • ウィルス学的検査
  • 血清学的検査
  • ヘルペス脳炎の検査

第7章 パイプライン分析

第8章 製品発売/認可

第9章 最近の業界活動

第10章 世界の主要プレーヤへの焦点

第11章 世界市場展望

  • 米国
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • スペイン
    • ロシア
    • その他
  • その他の地域

第12章 競合状況

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MCP-6451

This report analyzes the worldwide markets for Herpes Simplex Virus Treatment in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 38 companies including many key and niche players such as Agenus, Inc., AiCuris GmbH & Co.KG, Astellas Pharma, Inc., BioVex, Clinigen Group, Cytogenix, Inc., Genocea Biosciences, GlaxoSmithKline Plc, Lumavita AG, NanoBio Corporation, NanoViricides, Inc., Novartis International AG, Sanofi, Starpharma Holdings Limited, and Vical. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
    • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • A Prelude to Herpes Simplex Virus Infection
  • Prevalence
  • HSV Treatment
  • Patent Expiries Of Select Leading HSV Therapeutics
  • Leading HSV Drug (Valtrex) Sales Decline Due to Generic Competition
    • Table 1: Leading Drugs in the Global Herpes Simplex Therapeutics Market (2007-2010): Value Sales for Valtrex/Zelitrex, Zovirax in US$ Million (includes corresponding Graph/Chart)
    • Table 2: US Sales of Zovirax Products (2009 & 2010) in US$ Million
    • Table 3: European Sales of Aldara (2008-2010) in US$ Million (includes corresponding Graph/Chart)
  • HSV2 Pipeline Analysis

2. TREATMENT OF HERPES SIMPLEX VIRUS INFECTION

  • Antiviral Treatment
  • Major Drugs
  • Valtrex (Valacyclovir)
    • Table 4: Global Sales of Valtrex: 2002-2008 (includes corresponding Graph/Chart)
  • Zovirax (Acyclovir)
    • Table 5: Global Sales Of Zovirax: 2002-2007 (includes corresponding Graph/Chart)
  • Famvir (Famciclovir)
  • Foscarnet (Foscavir)
  • Abreva (Docosanol)
  • Cidofovir (Vistide)
  • Denavir/ Vectavir (Penciclovir)
  • Herpid
  • Orajel Medicated Cold Sore Brush
  • Viroxyn
  • Vaccination
  • Natural Treatment
  • Other Treatment

3. HSV VACCINES - AN INSIGHT

  • List of Select Pipeline Therapeutic Vaccines for the Treatment of HSV-2
  • Select Clinical Trials' Activity in the Herpes Simplex Vaccines Space
  • GSK to Discontinue Development of Simplirix™
  • GSK Initiates Phase III clinical Studies of Herpes Zoster Vaccine
  • Vical Presents Results from HSV-2 Vaccine Program
  • BioVex Begins Phase I Clinical Trial for Immuno VEXHSV2
  • Acambis Begins Preclinical Testing of HSV Vaccine

4. HERPES SIMPLEX VIRUS INFECTION - THE DISEASE, CAUSES, SYMPTOMS, AND DIAGNOSIS

  • Introduction
  • Structure of Herpes Virus
  • Biological Properties of Herpes Viruses
  • Different Types of Human Herpes Viruses
  • Latency in Herpes Virus Family
  • Antibody Response
  • HSV-1 and HSV-2 Infections
  • Causes
  • The Different Types of Herpes Infections
  • Oral Herpes
    • Transmission
    • Symptoms
  • Orolabial HSV Infections
    • Recurrent Orolabial Herpetic Infection
  • Genital Infections
    • Primary Genital Infection
    • Recurrent Genital Infection
      • Recurrent Genital Infections in Males
      • Recurrent Genital Infections in Females
    • Prevention
    • Diagnosis
  • HSV CNS Infection
  • Herpes Gladiatorum in Adolescent Wrestlers
  • Acute Herpetic Infections
    • Acute Herpetic Gingivostomatitis
    • Acute Herpetic Pharyngotonsillitis
  • HSV Infection in Neonates
  • Disseminated HSV Disease
  • Other HSV Infections
  • Herpes Whitlow
  • Primary Eye HSV Infection
  • HSV Infections In Different Age Groups
  • HSV Infection in Pregnant Women
  • HSV in Immunocompromised Patients
  • Morbidity and Mortality
  • Seriousness of Herpes Simplex Infection
  • Preventive Measures
  • Diagnosis of HSV Infection
  • Virologic Tests
    • Tzanck Smear Test
    • Polymerase Chain Reaction Tests
  • Serologic Tests
    • Biokit HSV-2
    • HerpeSelect
    • Western Blot Test
    • Type-Specific Assays Test
  • Tests for Herpes Encephalitis
    • Imaging Tests
    • Brain Biopsy
    • PCR

5. PIPELINE ANALYSIS

  • VivaGel Vaginal Microbicide
  • VivaGel® Retains Anti-viral Activity Against HSV and HIV
  • Simplivir™
  • HerpeCide
  • NB-001
  • Helicase-Primase Inhibitors

6. PRODUCT LAUNCHES AND APPROVALS

  • Medivir Launches 'Xerese' Cream for Cold Sores in the US
  • Actavis Launches Valaciclovir in Switzerland
  • Matrix Labs Receives FDA Approval for Valacyclovir Hydrochloride Tablets
  • Ranbaxy Pharmaceuticals Launches Valacyclovir Hydrochloride into US Market
  • Sirion Therapeutics Secures US FDA Approval for ZirganTM 0.15%
  • Meridian Life Science Introduces Herpes Simplex Virus Antigens

7. RECENT INDUSTRY ACTIVITY

  • Amgen Acquires BioVex
  • Antigenics Changes Name to Agenus
  • Clinigen Signs Agreement with AstraZeneca for Purchase of Foscavir
  • NanoViricides Inks R&D Deal with Dr. Ken S. Rosenthal's Laboratory
  • New American Therapeutics Purchases US Rights of Denavir
  • GlaxoSmithKline Acquires Xeclear Marketing Rights from Medivir
  • Bausch & Lomb Acquires Zirgan® Marketing Rights for the US Market
  • Genocea In-Licenses HSV Patent Estate from University of Washington
  • Medivir Teams Up with Meda for Marketing Xerese in the US
  • GSK and NanoBio Ink Licensing Deal for NB-001
  • Mymetics Takes Over Bestewil Holding
  • Sanofi Pasteur Acquires Acambis
  • Profectus Enters into an Assignment and License Deal with Wyeth

8. FOCUS ON SELECT GLOBAL PLAYERS

  • Agenus, Inc. (US)
  • AiCuris GmbH & Co.KG (Germany)
  • Astellas Pharma, Inc. (Japan)
  • Clinigen Group (UK)
  • Cytogenix, Inc. (US)
  • Genocea Biosciences (US)
  • GlaxoSmithKline Plc. (UK)
  • Lumavita AG (Switzerland)
  • NanoBio Corporation (US)
  • NanoViricides, Inc. (US)
  • Novartis International AG (Switzerland)
  • Sanofi (France)
  • Starpharma Holdings Limited (Australia)
  • Vical (US)

9. GLOBAL MARKET PERSPECTIVE

    • Table 6: World Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market by Geographic Region - US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 7: World Historic Review for Herpes Simplex Virus Treatment Market by Geographic Region - US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 8: World 15-Year Perspective for Herpes Simplex Virus Treatment Market by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Herpes Simplex Infection Increases in the US
    • HSV Infections In Different Races
    • Valtrex Dominates US HSV Prescription Market
    • Table 9: Leading Drugs in US Herpes Therapeutics Market (2011): Percentage Breakdown of New Prescriptions for Valtrex, Acyclovir, Zovirax, Aldara, Denavir, and Famvir (includes corresponding Graph/Chart)
    • Product Launches
    • Clinical Trials
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 10: The US Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 11: The US Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2. EUROPE

  • Market Analytics
    • Table 12: European Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market by Geographic Region - France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 13: European Historic Review for Herpes Simplex Virus Treatment Market by Geographic Region - France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 14: European 15-Year Perspective for Herpes Simplex Virus Treatment Market by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia & Rest of Europe Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

2a. FRANCE

  • A. Market Analysis
    • Key Player
  • B. Market Analytics
    • Table 15: French Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 16: French Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2b. GERMANY

  • A. Market Analysis
    • Key Player
  • B. Market Analytics
    • Table 17: German Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 18: German Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2c. ITALY

  • Market Analytics
    • Table 19: Italian Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 20: Italian Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2d. THE UNITED KINGDOM

  • A. Market Analysis
    • Clinical Trials
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 21: The UK Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 22: The UK Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2e. SPAIN

  • Market Analytics
    • Table 23: Spanish Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 24: Spanish Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2f. RUSSIA

  • Market Analytics
    • Table 25: Russian Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 26: Russian Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

2g. REST OF EUROPE

  • A. Market Analysis
    • Product Launch
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 27: Rest of European Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 28: Rest of European Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

3. REST OF WORLD

  • A. Market Analysis
    • Clinical Trial
    • Key Players
  • B. Market Analytics
    • Table 29: Rest of World Recent Past, Current & Future Analysis for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 30: Rest of World Historic Review for Herpes Simplex Virus Treatment Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top